Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445, a Factor Xa (fXa) Inhibitor Antidote
Conditions
Interventions
PRT064445
Placebo
Locations
1
United States
Phoenix, Arizona, United States
Start Date
June 1, 2012
Primary Completion Date
September 1, 2012
Completion Date
October 1, 2012
Last Updated
August 4, 2023
NCT00104325
NCT07470866
NCT07388667
NCT06637865
NCT07221448
NCT07118891
Lead Sponsor
Portola Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions